Why does marketing a personal sound amplification product with hearing-loss claims trigger FDA regulation?

Personal sound amplification products, or PSAPs, are intended for situational sound amplification for people with normal hearing and are not regulated as medical devices, but the moment a manufacturer markets such a product with claims about compensating for hearing loss or hearing impairment, FDA considers it a hearing aid subject to the applicable hearing-aid regulatory pathway, whether OTC or prescription. This distinction is based on intended use claims rather than the device's underlying technology, so marketing language alone can shift a product's regulatory status.

Are pediatric hearing aids covered by the OTC rule?

No, the OTC hearing aid rule applies only to adults with perceived mild-to-moderate hearing loss, and pediatric hearing aids remain prescription-only devices requiring a medical evaluation and professional fitting, since hearing loss in children carries different diagnostic and developmental considerations that the OTC pathway was not designed to address. Manufacturers developing hearing devices that could reach pediatric users need separate labeling and marketing controls to ensure the product is not inadvertently sold or marketed for pediatric use under the OTC framework.

Why does Medicare's limited hearing aid coverage matter for market strategy?

Because Medicare does not cover most hearing aids, a substantial portion of the addressable population must pay out of pocket or rely on secondary insurance or Medicare Advantage supplemental benefits, which creates uneven and plan-dependent coverage that materially affects pricing strategy and channel decisions compared to devices with more standardized insurance coverage. Companies entering the hearing device market generally need a payer-by-payer and channel-specific commercialization plan rather than assuming standard Medicare fee-for-service reimbursement will apply.

All terms

Market SegmentsStrategic Landscape

Hearing Devices

Air-conduction and bone-conduction hearing aids, OTC hearing aids, and cochlear implants, spanning Class I, II, and III pathways.

Reviewed by Christian Espinosa, Founder, Blue Goat CyberLast reviewed May 9, 2026

Definition

The hearing-devices segment covers prescription air-conduction hearing aids, the FDA-created OTC hearing aid category (effective October 2022 under 21 CFR 800.30), bone-anchored hearing systems, and cochlear implants. The 2022 OTC rule fundamentally restructured the consumer end of the market by allowing direct-to-consumer sale of mild-to-moderate hearing-loss devices to adults without an audiologist visit.

What the regulation says

21 CFR 800.30 (OTC hearing aids), 21 CFR 874.3300 (prescription hearing aids), and 21 CFR 874.3450 (bone-conduction). Cochlear implants are Class III PMA devices under product code MCM.

What this means in practice

OTC hearing aids brought new entrants (Apple AirPods Pro hearing-aid feature, Sony, Bose) and price compression on traditional prescription products. Insurance coverage remains uneven; Medicare does not cover most hearing aids.

Examples

A patient with severe hearing loss might receive an implantable device designed to stimulate the auditory nerve directly, representing a Class III device within this segment.
Many adults with newly identified mild-to-moderate hearing loss are now exploring non-prescription devices available directly from retailers, circumventing the need for an audiologist visit.
Advanced prescription devices often incorporate sophisticated digital signal processing to filter background noise and enhance speech clarity for individuals with moderate to profound hearing impairments.

Common pitfalls

•Marketing personal sound amplification products (PSAPs) with hearing-loss claims, that triggers FDA hearing-aid regulation.
•Forgetting that pediatric hearing aids remain prescription-only under the OTC rule.

Frequently asked questions

The FDA's OTC hearing aid rule, effective under 21 CFR 800.30 in October 2022, created a new regulatory category allowing adults with perceived mild-to-moderate hearing loss to purchase certain hearing aids directly, without a medical exam, audiologist fitting, or prescription, fundamentally restructuring a market that previously required a professional visit for any hearing aid purchase. This opened the category to new consumer electronics entrants and drove price compression in the traditional prescription hearing aid segment, while leaving prescription-only requirements in place for more severe hearing loss and for pediatric patients.

Grouped by theme

Editor's picks

· Hand-selected related concepts

Regulatory

510(k) Premarket Notification(510(k))

FDA submission demonstrating a device is substantially equivalent to a legally marketed predicate.

Regulatory

Premarket Approval(PMA)

FDA's most stringent device marketing application, required for high-risk Class III devices.

Latest in MedTech

Sources

3 sources

Sources support the definition or relevant regulatory context, not necessarily every claim on this page. Each is graded against our source-tier hierarchy so you can see what rests on binding law versus commentary.

Tier 2Regulator guidance and consensus· 1Tier 4Trade press and expert commentary· 2

Link health: 3 verified· last checked 2026-06-20

FDA·1MedTech Europe·1MedTech Dive·1

Inline markers like [1] jump to the matching reference above.

My progress

All terms0 / 513

Market Segments0 / 38

Saved on this device, and to your account when signed in. View studied terms

Full glossary

Browse all terms A to Z, each with a short definition.

On this term

Category: Market Segments
Sources: 3
Updated: 5/9/2026

Compare with another term

Learn in 60 seconds

Air-conduction and bone-conduction hearing aids, OTC hearing aids, and cochlear implants, spanning Class I, II, and III pathways.

·OTC hearing aids brought new entrants (Apple AirPods Pro hearing-aid feature, Sony, Bose) and price compression on traditional prescription products.
·Insurance coverage remains uneven; Medicare does not cover most hearing aids.
·The 2022 OTC rule fundamentally restructured the consumer end of the market by allowing direct-to-consumer sale of mild-to-moderate hearing-loss devices to adults without an audiologist visit.

Remember this

Watch out: Marketing personal sound amplification products (PSAPs) with hearing-loss claims, that triggers FDA hearing-aid regulation.

Related terms

You may also need

Auto-suggested from Market Segments and shared keywords.

All Market Segments terms